Efficacy of sacituzumab govitecan based regimen in triple-negative breast cancer: A systematic review.

被引：0
|
作者：
Khalid, Farhan
Kashyap, Richi
Singh, Vinit
Tayyeb, Muhammad
Jaan, Ali
Mohan, Gaurav
Meghal, Trishala
机构：
[1] Monmouth Med Ctr, Dept Internal Med, Long Branch, NJ USA
[2] North Alabama Med Ctr, Dept Internal Med, Florence, AL USA
[3] Rochester Gen Hosp, Dept Internal Med, Rochester, NY USA
[4] Monmouth Med Ctr, Dept Med, Sect Hematol, Long Branch, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13068
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sacituzumab govitecan: a new antibody-drug conjugate for metastatic triple-negative breast cancer
    Banys-Paluchowski, M.
    Krawczyk, Natalia
    ONKOLOGE, 2021, 27 (03): : 287 - 290
  • [22] Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients
    Altundag, Kadri
    BREAST CANCER, 2024, 31 (04) : 735 - 735
  • [23] Metastatic triple-negative breast cancer (mTNBC) first-in-class therapy with sacituzumab govitecan
    Schoellmann, Claudia
    BREAST CARE, 2022, 17 (01)
  • [24] Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
    Chen, Jigang
    Han, Mingyang
    Liu, Aihua
    Shi, Bo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [25] A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
    Bardia, Aditya
    Hurvitz, Sara A.
    Rugo, Hope S.
    Brufsky, Adam
    Cortes, Javier
    Loibl, Sibylle
    Piccart, M.
    Cowden, Janice
    Spears, Patty
    Carey, Lisa A.
    FUTURE ONCOLOGY, 2021, 17 (30) : 3911 - 3924
  • [26] Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine
    Khan, Saif
    Jandrajupalli, Suresh Babu
    Bushara, Nashwa Zaki Ali
    Raja, Rama Devi Patel
    Mirza, Shadab
    Sharma, Kuldeep
    Verma, Rajan
    Kumar, Ashish
    Lohani, Mohtashim
    CELLS, 2024, 13 (24)
  • [27] Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study
    Carrion-Madronal, Isabel Maria
    Diaz-Acedo, Rocio
    Lora-Escobar, Santiago Jose
    Naranjo-Llamas, Eloisa
    Jaramillo-Ruiz, Didiana
    Artacho-Criado, Silvia
    Prado-Mel, Elena
    FUTURE ONCOLOGY, 2024, 20 (33) : 2565 - 2572
  • [28] Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors
    Sathe, Abhishek G.
    Singh, Indrajeet
    Singh, Pratap
    Diderichsen, Paul M.
    Wang, Xiaohui
    Chang, Peter
    Taqui, Atiya
    Phan, See
    Girish, Sandhya
    Othman, Ahmed A.
    CLINICAL PHARMACOKINETICS, 2024, 63 (05) : 669 - 681
  • [29] Sacituzumab govitecan response in extensive leptomeningeal carcinomatosis from triple-negative breast cancer: a case report
    Yaringano, Jesus
    Roca-Herrera, Maria
    Eremiev, Simeon
    Mascaro-Baselga, Pau
    Benito, Pau
    Nunez, Fidel
    Benavente, Sergi
    Pimentel, Isabel
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [30] Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors
    Fenn, K. M.
    Kalinsky, K.
    DRUGS OF TODAY, 2019, 55 (09) : 575 - 585
12345